News
PEN
239.99
+1.06%
2.51
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
NASDAQ · 10h ago
Here's Why You Should Hold IART Stock in Your Portfolio Now
NASDAQ · 12/31/2024 11:32
Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects
Simply Wall St · 12/31/2024 10:51
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire · 12/30/2024 21:30
New Product Offerings Support QIAGEN's Shares Amid Currency Woes
NASDAQ · 12/30/2024 15:49
STERIS Gains From Expanded Product Offerings Amid Macro Issues
NASDAQ · 12/30/2024 15:27
Reasons to Retain AMED Stock in Your Portfolio Now
NASDAQ · 12/30/2024 12:17
Weekly Report: what happened at PEN last week (1223-1227)?
Weekly Report · 12/30/2024 09:24
Growing Biosimilars Business, New Partnerships Support ABT Stock
NASDAQ · 12/27/2024 13:46
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
NASDAQ · 12/27/2024 12:17
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
NASDAQ · 12/26/2024 15:27
Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock
NASDAQ · 12/26/2024 14:51
Lucid Inks New Partnership With VITALExam: Stock to Gain?
NASDAQ · 12/26/2024 12:23
(PEN) - Analyzing Penumbra's Short Interest
Benzinga · 12/24/2024 19:30
Here's Why You Should Add HAE Stock to Your Portfolio Now
NASDAQ · 12/24/2024 12:44
Reasons to Add GMED Stock to Your Portfolio Right Now
NASDAQ · 12/24/2024 12:44
Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?
NASDAQ · 12/24/2024 12:17
Penumbra CEO sells $3.64M in common stock
TipRanks · 12/24/2024 01:15
Align Shares Down on Macroeconomic Issues, ASP Challenges
NASDAQ · 12/23/2024 14:35
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
NASDAQ · 12/23/2024 13:02
More
Webull provides a variety of real-time PEN stock news. You can receive the latest news about Penumbra Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEN
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.